Market Update Close: The market failed to hold onto modest midday gains as the absence of spirited leadership amid mixed economic data and company guidance closed the indices near their worst levels of the session. Before the bell, core-PPI unexpectedly fell 0.3% - the largest one-month decline in more than two years, easing inflation fears. Nevertheless, before investors could use a tame producer inflation read as a catalyst to justify an average three-week, 4.9% advance for the major indices and lend further support to Briefing.com's anticipation of a traditional year-end rally, the market awaited...
Grab-and-Go Breakfast. The key to any healthy grab-and-go meal is a balance of protein, fat and carbs. For a quick and easy breakfast, stuff half a whole-wheat pita with cottage cheese and sliced peaches or pears.
More
JESSICA'S DIVA DEMANDS
Jessica Simpson, 25, likes to act clueless, but she can swing her celebrity weight like a pro. According to a studio source, weeks before the press tour for The Dukes of Hazzard began, "we were bombarded with a six-page pamphlet of demands for Jessica from the office of her dad, Joe Simpson." Among Jessica's requests: paid accommodations for her hairstylist and assistant in the same hotel as Jessica; a wardrobe budget estimated in the thousands of dollars; cases of Evian water; and paid private... JEN FREAKS OVER ANGELINA'S NEW BABY JULIA STILES, GWYNETH PALTROW AND MORE!
Senate Urges Bush to Outline Iraq Plan US soldiers block a highway after a road side bomb exploded in Al-Baladyaat district, targeting a patrol of the Iraqi army, in Baghdad, Iraq, Tuesday, Nov. 15, 2005. According to Iraqi police four people were injured by the blast. (AP Photo/Hadi Mizban)
9:54 pm PT On The Wires :Enbridge Energy Partners (EEP) announces that it has launched an offering through underwriters of 3.0 mln Class A Common Units representing limited partner interests... Sun Healthcare Group (SUNH) announces that it has successfully obtained regulatory approvals in all states in which Peak Medical operates with the exception of Oklahoma... American Community Properties Trust (APO) announces that it will restate its audited financial statements for the years ended December 31, 2002, 2003 and 2004, and its unaudited financial statements for the two previously reported quarters of 2005 to correct previously reported amounts related to income tax matters... Equity One (EQY) announces that 362,357 ordinary shares, representing 4.9% of the outstanding share capital of DIM Vastgoed N.V., have been tendered in connection with EQY's offer to acquire all of the outstanding ordinary shares for $20.50 per share... Pomeroy IT Solutions (PMRY) announces that it has filed a Form 12b-25 notifying the SEC that it has not met the November 14, 2005 deadline to file its quarterly report on Form 10-Q for the fiscal quarter ended October 5, 2005.
9:41 pm PT American BioScience Licenses ABRAXANE to Taiho Pharma (APPX) 45.55 :American BioScience announces it has licensed ABRAXANE to Taiho Pharma and established a Joint Steering Committee with Taiho which will oversee the development of ABRAXANE in Japan for the treatment of breast, lung, gastric, and other solid tumors. ABRAXANE is being commercialized in North America by Abraxis Oncology, a division of American Pharmaceutical Partners (APPX). Under the terms of the license agreement, American BioScience will receive upfront and milestone payments in excess of $50 mln, in addition to substantial royalties. The co also will supply ABRAXANE for the Japanese market.
9:35 pm PT Favrille announces new data from phase 2 clinical trial of FavId (FVRL) 3.50 :Co announces the online publication of its abstract containing long-term follow-up data from Phase 2 clinical trial of FavId following Rituxan therapy in patients with follicular B-cell non-Hodgkin's lymphoma. A total of 103 patients were enrolled in this Phase 2 trial, of which 89 had a stable disease or better response to Rituxan and received FavId, including 55 who were relapsed from or refractory to prior treatments and 34 who were treatment-naive. The overall clinical response rate measured in the trial increased from 49 percent following Rituxan alone to 64 percent with the addition of FavId.